Analyst Profile

Followed by 4,995 followers
.
Joseph Pantginis

Joseph Pantginis

H.C. Wainwright
Wall Street Analyst
#8,066 out of 8,160 Wall Street Analysts
#23,972 out of 24,427 experts

Success Rate

33%
126 out of 384 transactions made a profit

Average Return

-16.10%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Joseph Pantginis's trades since 2010 and holding each position for 1 Year would result in 32.81% of your transactions generating a profit, with an average return of -16.1% per rating.

Stock Rating Distribution

3KRatings
95.75% Buy
3.95% Hold
0.30% Sell
Distribution of Joseph Pantginis's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market
CanadaCanadian Market
United KingdomUK Market

Best Rating

Stock:
AKOUOS INC
(AKUS)
Rating:Buy
Date:May 12, 2022 - Oct 18, 2022
Return:+287.90%
The most profitable rating made by Joseph Pantginis

Joseph Pantginis's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
Cyclacel Pharmaceuticals
Feb 04, 2010
Buy
Initiated
$7.00
(788.66% Upside)
1Ratings
0.00%
Microbot Medical
Jul 24, 2012
Buy
Reiterated
$5.00
(11.11% Upside)
2Ratings
0.00%
Amarin
Sep 11, 2012
Buy
Reiterated
$26.00
(2112.77% Upside)
1Ratings
0.00%
Agenus
Nov 09, 2012
Buy
Reiterated
1Ratings
0.00%
LadRx
Sep 30, 2013
Buy
Reiterated
$9.00
(5273.13% Upside)
1Ratings
0.00%
Travere Therapeutics
Apr 14, 2014
Buy
Reiterated
$51.00
(154.87% Upside)
3Ratings
0.00%
DNDNQ
Dendreon Corp
Nov 12, 2014
Hold
Upgraded
7Ratings
0.00%
PCYC
Pharmacyclics
Feb 18, 2015
Hold
Reiterated
16Ratings
0.00%
MEI Pharma
Mar 23, 2015
Hold
Downgraded
$2.50
(517.28% Upside)
9Ratings
0.00%
Can-Fite BioPharma
May 31, 2015
Hold
Reiterated
$3.30
(305.11% Upside)
10Ratings
0.00%
List of latest recommendations made by Joseph Pantginis. Click to expand and see Joseph Pantginis's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >